Cardiac Electrophysiology team performs the system’s first FDA approved pulsed field ablation system
We’re proud to announce that our Cardiac Electrophysiology team performed the system’s first procedure utilizing the PulseSelect Pulsed Field Ablation (PFA) system, recently FDA approved for treating both paroxysmal and persistent atrial fibrillation.
Atrial fibrillation is one of the most common and undertreated heart rhythm disorders, affecting more than 60 million people worldwide. Atrial fibrillation is a progressive disease, meaning it can become worse over time and can increase the risk of serious complications including heart failure, stroke and increased risk of death. Current ablation technologies rely on thermal effects to target cardiac tissue and risk damage to additional collateral structures in the heart. PFA is a breakthrough ablation technology that uses pulsed electric fields to efficiently isolate the pulmonary veins for the treatment of atrial fibrillation. Because the mechanism of cell death is non-thermal, the risk of collateral structure damage is potentially lower.
The PulseSelect PFA system was engineered with differentiated safety features and provides rapid, effective pulmonary vein isolation (PVI) through consistent and predictable energy delivery and catheter maneuverability. The system is designed to enable a seamless transition to PFA in a clinician’s preferred workflow. The PulseSelect PFA system’s safety, efficacy, and efficiency is supported by the PULSED AF study, which showed a 0.7% safety event rate and clinical success rates of 80% in both paroxysmal and persistent atrial fibrillation patients.
Congratulations to the cardiac electrophysiology team in utilizing new, advanced systems for better care.